100 completed, 43 terminated, 30 active not recruiting, 18 recruiting. 212 Phase 1, 94 Phase 2.
Follow Rituxan: new trials by email Literature Review of Rituxan trials Research Report on Rituxan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-10-28 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia Rituximab - PTLD, Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Jennifer Amengual | 28 | 2026-12-01 | 2026-09-17 |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Utah | 23 | 2026-11-01 | 2026-10-09 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL Capivasertib, Venetoclax, Rituximab - Leukemia, Lymphoma | Phase 1 / Phase 2 | Recruiting | University of Chicago | 104 | 2026-03-17 | 2026-03-04 |
| SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas SB-4826, Rituximab - Non Hodgkin Lymphoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of California, San Diego | 48 | 2026-02-18 | 2026-03-05 |
| Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Zanubrutinib, Rituximab, Obinutuzumab - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | University of Utah | 24 | 2025-09-12 | 2026-06-30 |
| Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma N803, CD19t-haNK suspension, Cyclophosphamide - Non Hodgkin's Lymphoma Refractory/Relapsed | Phase 1 | Recruiting | ImmunityBio, Inc. | 20 | 2025-08-22 | 2026-04-01 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL Pembrolizumab, Methotrexate, Temozolomide - Lymphoma, Primary Central Nervous System Lymphoma | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 15 | 2024-10-18 | 2026-10-23 |
| CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2024-01-29 | 2026-02-27 |
| FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) FT522, Rituximab, Cyclophosphamide - Relapsed/Refractory B-Cell Lymphoma | Phase 1 | Completed | Fate Therapeutics | 20 | 2023-11-16 | 2025-08-22 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) Polatuzumab vedotin, Rituximab, CHP - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Active not recruiting | Washington University School of Medicine | 12 | 2023-10-04 | 2026-06-30 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma Rituximab, Lenalidomide, Valemetostat - Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 16 | 2023-05-19 | 2026-06-29 |
| CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab - Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2023-05-01 | 2026-03-06 |
Showing 20 of 212. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (56) · Lymphoma, Large B-Cell, Diffuse (50) · Lymphoma (45) · Lymphoma, Non-Hodgkin (45) · Lymphoma, Mantle-Cell (42) · Lymphoma, Follicular (40) · Lymphoma, B-Cell, Marginal Zone (27) · Leukemia (24) · Waldenstrom Macroglobulinemia (22) · Lymphoma, B-Cell (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (21) · Hodgkin Disease (20) · Burkitt Lymphoma (19) · Recurrence (11) · Lymphoma, Large-Cell, Immunoblastic (10)
M.D. Anderson Cancer Center (39) · National Cancer Institute (NCI) (34) · Northwestern University (8) · Dana-Farber Cancer Institute (7) · Mayo Clinic (7) · City of Hope Medical Center (5) · Fate Therapeutics (4) · Massachusetts General Hospital (4) · University of Washington (4) · Masonic Cancer Center, University of Minnesota (3) · OHSU Knight Cancer Institute (3) · Paul Szabolcs (3) · SCRI Development Innovations, LLC (3) · University of California, San Francisco (3) · Washington University School of Medicine (3)
United States (197) · Italy (4) · Spain (4) · Australia (3) · France (3) · Germany (3) · India (3) · Switzerland (3) · United Kingdom (3) · Austria (2) · Canada (2) · Hungary (2) · Poland (2) · South Korea (2) · Argentina (1)
Richard Burt, MD (3) · Andre Goy, MD (2) · Brian Hill, MD, PhD (2) · E. Steve Woodle, MD (2) · Elizabeth Shpall, MD (2) · Issa F. Khouri, MD (2) · Kami Maddocks, MD (2) · Lakshmi Nayak, MD (2) · Mehrdad Abedi (2) · Paul Szabolcs, MD (2) · Ryan Lynch (2) · Sonali Smith (2) · Thomas Witzig (2) · Veronika Bachanova, MD (2)
PMID 34515338, PMID 21816833, PMID 22586182, PMID 22677155, PMID 22775314, PMID 23197589, PMID 23234514, PMID 23334994, PMID 23592273, PMID 23834234, PMID 25145344, PMID 25355819, PMID 25667206, PMID 25778529, PMID 26071868, PMID 26139427, PMID 27018242, PMID 27118452, PMID 27697771, PMID 28314788, PMID 28637670, PMID 29032710, PMID 29296805, PMID 29386196, PMID 29476021, PMID 29610115, PMID 29986852, PMID 30826465, PMID 31723767, PMID 31915195, PMID 32052313, PMID 32126141, PMID 32430507, PMID 32785680, PMID 33318163, PMID 33478921, PMID 33586581, PMID 33676628, PMID 33951890, PMID 34398557, PMID 34608724, PMID 34634256, PMID 35595730, PMID 35787017, PMID 35835137, PMID 36180329, PMID 36521030, PMID 36841758, PMID 37192437, PMID 37407001
P30CA033572 (4), U01CA076576 (4), P30CA015083 (3), P30CA016672 (3), P30CA060553 (3), U10CA180821 (3), UM1CA121947 (3), UM1CA186717 (3), 2017 (2), P01CA148600 (2), P30CA008748 (2), P50CA107399 (2), 2009 (1), 2015 (1), 2018 (1)